The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.51%....
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten...
/2d%20illustration%20of%20Cloud%20computing%20by%20Blackboard%20via%20Shutterstock.jpg)
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.26%. December E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is up by +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.50%. December E-mini S&P futures...
Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p
Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s management...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September...
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation...